Plaque Psoriasis Pipeline Review | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook | Bio-Thera Solutions, Jiangsu HengRui Medicine, Arcutis Biotherapeutics

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Plaque Psoriasis pipeline constitutes 75+ key companies continuously working towards developing 75+ Plaque Psoriasis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Plaque Psoriasis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Plaque Psoriasis Market.

The Plaque Psoriasis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Plaque Psoriasis Pipeline Report: https://www.delveinsight.com/sample-request/plaque-psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Plaque Psoriasis treatment therapies with a considerable amount of success over the years.
• Plaque Psoriasis companies working in the treatment market are Azora Therapeutics, Artax Biopharma Inc., Hangzhou Highlightll Pharmaceutical, Bio-Thera Solutions, Jiangsu HengRui Medicine, Arcutis Biotherapeutics, Jiangsu Hengrui Medicine, Akeso Biopharma, Dong-A ST Co., Ltd., Suzhou Zelgen Biopharma, Sun Pharma, Nimbus Therapeutics, Meiji Pharma, Affibody, GC Cell Corporation, and others, are developing therapies for the Plaque Psoriasis treatment
• Emerging Plaque Psoriasis therapies in the different phases of clinical trials are- AT193, AX-158, TLL018, BAT2306, SHR-1314, ARQ-151, SHR 1314, AK101, DMB-3115, Jaktinib, SCD-044, NDI 034858, ME3183, ABY-035, CT 303, and others are expected to have a significant impact on the Plaque Psoriasis market in the coming years.
• In February 2024, Johnson & Johnson announced the publication of Phase 2b FRONTIER 1 trial results for JNJ-2113 in the New England Journal of Medicine (NEJM). JNJ-2113 is the first investigational targeted oral peptide inhibitor designed to block the IL-23 receptor. IL-23 is crucial in activating pathogenic T-cells in moderate-to-severe plaque psoriasis (PsO) and contributes to the inflammatory response in PsO and other IL-23-mediated dermatological and gastroenterological diseases. The FRONTIER 1 trial successfully met its primary and all secondary efficacy endpoints in evaluating JNJ-2113 for adults with moderate-to-severe plaque PsO.
• In October 2023, Bristol Myers Squibb has reported three-year results from the POETYK PSO long-term extension trial (NCT04036435) evaluating Sotyktu (deucravacitinib) for moderate-to-severe plaque psoriasis. Deucravacitinib is an oral medication that selectively targets tyrosine kinase 2 (TYK2) to inhibit key cytokines involved in the biological pathways of immune-mediated diseases like psoriasis.

Plaque Psoriasis Overview
Psoriasis vulgaris, also known as plaque psoriasis, is a persistent (chronic) autoimmune condition that accelerates cell division. It is a kind of psoriasis that results in plaques on the skin, which are thick, scaly regions. Approximately 8 million Americans suffer from the skin condition psoriasis.

Get a Free Sample PDF Report to know more about Plaque Psoriasis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/plaque-psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Plaque Psoriasis Drugs Under Different Phases of Clinical Development Include:
• AT193: Azora Therapeutics
• AX-158: Artax Biopharma Inc.
• TLL018: Hangzhou Highlightll Pharmaceutical
• BAT2306: Bio-Thera Solutions
• SHR-1314: Jiangsu HengRui Medicine
• ARQ-151: Arcutis Biotherapeutics
• SHR 1314: Jiangsu Hengrui Medicine
• AK101: Akeso Biopharma
• DMB-3115: Dong-A ST Co., Ltd.
• Jaktinib: Suzhou Zelgen Biopharma
• SCD-044: Sun Pharma
• NDI 034858: Nimbus Therapeutics
• ME3183: Meiji Pharma
• ABY-035: Affibody
• CT 303: GC Cell Corporation

Plaque Psoriasis Route of Administration
Plaque Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Plaque Psoriasis Molecule Type
Plaque Psoriasis Products have been categorized under various Molecule types, such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Plaque Psoriasis Pipeline Therapeutics Assessment
• Plaque Psoriasis Assessment by Product Type
• Plaque Psoriasis By Stage and Product Type
• Plaque Psoriasis Assessment by Route of Administration
• Plaque Psoriasis By Stage and Route of Administration
• Plaque Psoriasis Assessment by Molecule Type
• Plaque Psoriasis by Stage and Molecule Type

DelveInsight's Plaque Psoriasis Report covers around 75+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Plaque Psoriasis product details are provided in the report. Download the Plaque Psoriasis pipeline report to learn more about the emerging Plaque Psoriasis therapies
https://www.delveinsight.com/sample-request/plaque-psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Plaque Psoriasis Therapeutics Market include:
Key companies developing therapies for Plaque Psoriasis are - Arcutis Biotherapeutics, Affibody, Akeso Biopharma, Dong-A ST Co., Ltd., DelArrivo, Inc., Bristol-Myers Squibb, Bio-Thera Solutions, Janssen Research & Development, LLC, Meiji Pharma USA Inc., Aldeyra Therapeutics, Inc., Amgen, Bioeq GmbH, Can-Fite Biopharma, Hangzhou Highlightll Pharmaceutical Co., Ltd, Nimbus Therapeutics, Sun Pharmaceutical Industries, Jiangsu Hengrui Medicine, Ono Pharmaceutical, GC Cell Corporation, Suzhou Zelgen Biopharmaceuticals, Aurigene Discovery Technologies Limited, Celltrion, Tianjin Hemay Pharmaceutical Co., Ltd, Innovent Biologics (Suzhou) Co. Ltd., Sinocelltech, Azora Therapeutics, Biocon, and others.

Plaque Psoriasis Pipeline Analysis:
The Plaque Psoriasis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Plaque Psoriasis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Plaque Psoriasis Treatment.
• Plaque Psoriasis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Plaque Psoriasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Plaque Psoriasis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Plaque Psoriasis drugs and therapies
https://www.delveinsight.com/sample-request/plaque-psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Plaque Psoriasis Pipeline Market Drivers
• Growing worldwide prevalence, ongoing research and development activities to identify novel and targeted therapies, increase in Awareness about the disease are some of the important factors that are fueling the Plaque Psoriasis Market.

Plaque Psoriasis Pipeline Market Barriers
• However, poor adherence and compliance with medications, challenging disease in terms of management and other factors are creating obstacles in the Plaque Psoriasis Market growth.

Scope of Plaque Psoriasis Pipeline Drug Insight
• Coverage: Global
• Key Plaque Psoriasis Companies: Azora Therapeutics, Artax Biopharma Inc., Hangzhou Highlightll Pharmaceutical, Bio-Thera Solutions, Jiangsu HengRui Medicine, Arcutis Biotherapeutics, Jiangsu Hengrui Medicine, Akeso Biopharma, Dong-A ST Co., Ltd., Suzhou Zelgen Biopharma, Sun Pharma, Nimbus Therapeutics, Meiji Pharma, Affibody, GC Cell Corporation, and others
• Key Plaque Psoriasis Therapies: AT193, AX-158, TLL018, BAT2306, SHR-1314, ARQ-151, SHR 1314, AK101, DMB-3115, Jaktinib, SCD-044, NDI 034858, ME3183, ABY-035, CT 303, and others
• Plaque Psoriasis Therapeutic Assessment: Plaque Psoriasis current marketed and Plaque Psoriasis emerging therapies
• Plaque Psoriasis Market Dynamics: Plaque Psoriasis market drivers and Plaque Psoriasis market barriers

Request for Sample PDF Report for Plaque Psoriasis Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/plaque-psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Plaque Psoriasis Report Introduction
2. Plaque Psoriasis Executive Summary
3. Plaque Psoriasis Overview
4. Plaque Psoriasis- Analytical Perspective In-depth Commercial Assessment
5. Plaque Psoriasis Pipeline Therapeutics
6. Plaque Psoriasis Late Stage Products (Phase II/III)
7. Plaque Psoriasis Mid Stage Products (Phase II)
8. Plaque Psoriasis Early Stage Products (Phase I)
9. Plaque Psoriasis Preclinical Stage Products
10. Plaque Psoriasis Therapeutics Assessment
11. Plaque Psoriasis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Plaque Psoriasis Key Companies
14. Plaque Psoriasis Key Products
15. Plaque Psoriasis Unmet Needs
16 . Plaque Psoriasis Market Drivers and Barriers
17. Plaque Psoriasis Future Perspectives and Conclusion
18. Plaque Psoriasis Analyst Views
19. Appendix
20. About DelveInsight

Latest Reports:

Aneurysmal Subarachnoid Hemorrhage Market https://www.delveinsight.com/report-store/aneurysmal-subarachnoid-hemorrhage-sah-market
DelveInsight's "Aneurysmal Subarachnoid Hemorrhage (SAH) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Aneurysmal Subarachnoid Hemorrhage (SAH), historical and forecasted epidemiology as well as the Aneurysmal Subarachnoid Hemorrhage (SAH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Angelman Syndrome Market https://www.delveinsight.com/report-store/angelman-syndrome-market-forecast
DelveInsight's "Angelman Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Angelman Syndrome, historical and forecasted epidemiology as well as the Angelman Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Autoimmune Pulmonary Alveolar Proteinosis Market https://www.delveinsight.com/report-store/autoimmune-pulmonary-alveolar-proteinosis-apap-market
DelveInsight's "Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Market Insights, Epidemiology and Market Forecast - 2032" report delivers an in-depth understanding of Autoimmune pulmonary alveolar proteinosis, historical and forecasted epidemiology as well as Autoimmune pulmonary alveolar proteinosis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Cardiovascular Calcification Market https://www.delveinsight.com/report-store/cardiovascular-calcification-market
DelveInsight's "Cardiovascular Calcification Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Cardiovascular Calcification, historical and forecasted epidemiology as well as the Cardiovascular Calcification market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Charcot Marie Tooth Disease Market https://www.delveinsight.com/report-store/charcot-marie-tooth-disease-market
DelveInsight's 'Charcot-Marie-Tooth Disease Market Insights, Epidemiology, and Market Forecast 2032' report deliver an in-depth understanding of the Charcot-Marie-Tooth Disease, historical and forecasted epidemiology as well as the Charcot-Marie-Tooth Disease market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.